Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Hum Mutat. 2019 Sep 15;40(12):2414–2429. doi: 10.1002/humu.23898

Figure 3.

Figure 3

PARN protein levels are variably reduced in LCLs containing the p.(I274*) mutation. (A) Western blot of whole cell extracts of BMF22 family members and unrelated control LCLs (RQ4115, 101M, 128S2, and 136S1). β-actin is a loading control. Boxes with diagonal lines obscure samples from family members or controls for which there were only 1 or 2 samples, and were, therefore, excluded from the analysis. (B) Quantification of western blots in (A) and Figure S4. Bars indicate mean PARN/β-actin ratio +/− standard deviation (SD) compared to 128S2 with N=3–7. ***p<0.001, ****p<0.0001, based on one-way ANOVA of log-transformed data followed by Dunnett’s post-hoc test and adjustment of p-values for multiple comparisons. (C) Analysis of PARN expression in BMF22 family and unrelated controls (128S2 and 136S1) LCLs by qRT-PCR. Complementary DNA was synthesized using oligo(dT) primer and qPCR was performed using primers to the target, PARN, or the control, GAPDH. Bars indicate mean +/− SD compared to 128S2 with N=3. **p=0.0053 and *p=0.0130. ns, not significant. p-values were calculated using one-way ANOVA of followed by Dunnett’s post-hoc test comparing F, M and G4 to S2 and adjustment of p-values for multiple comparisons.